Please assess the completion status of the following clinical trial:

Trial Title: Tofogliflozin GLP-1 Analogue Combination Trial

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* The subject aged from 20 to 75 years old with type 2 diabetes mellitus(T2DM)~* The subject with hemoglobin A1c ≧7.5% - \<10.5 %~* The subject who has been receiving a stable dose and regimen of GLP-1 analogue over 8 weeks before Screening test~Exclusion Criteria:~* The subject with type 1 diabetes mellitus~* The subject with Pregnancy or lactation~* The subject with Fasting Plasma Glucose ≧ 270 mg/dl~* The subject with history of metabolic acidosis, including diabetic ketoacidosis ,within 1 year prior to screening~* The subject with myocardial infarction, stroke, or heart failure requiring hospitalization or drug or alcohol abuse within the previous 6 months~* The subject with serum creatinine level greater than 2.0 mg/dL for men and 1.5 mg/dL for women~* The subject with aspartate aminotransferase(AST) or alanine aminotransferase(ALT) ≧ 2.5 times the upper limit of the reference range at the central laboratory test facility~* The subject has received treatment with another investigational product or non-approved drug 3 months before screening~* The subject with history of Tofogliflozin therapy~* The subject with estimated glomerular filtration rate of \<30 mL/min/1.73 m\^2~* The subject who frequently experiencing orthostatic hypotension~* The subject systolic blood pressure of ≧ 180 or mmHg of diastolic blood pressure of ≧ 100 mmHg~* The subject required a change in the dosing regiment for the following drugs within 4 weeks before screening : Lipid-lowering drug , Antihypertensive drug, Thyroid hormone drug , Uric acid lowering drug

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Tofogliflozin ＋GLP-1 analogue (Type: EXPERIMENTAL): Tofogliflozin administered once daily for 52 weeks. GLP-1 analogue administered as base treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).